S. P. Aix

发表

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First‐Line Platinum‐Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS‐lung Trial

H. Groen, V. Torri, U. Dafni, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

U. Dafni, R. Stahel, S. Peters, 2017, The Lancet. Respiratory medicine.

Randomized phase III trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels in patients with node positive resected non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial (Eudract:2007-000067-15; NCTgov: 00478699).

R. Rosell, B. Massuti, J. Sánchez-Payá, 2015 .

Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.

M. Socinski, N. Reinmuth, C. Gridelli, 2020, Clinical lung cancer.

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Young Hak Kim, N. Reinmuth, A. Chiang, 2019, The Lancet.

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

Keunchil Park, D. Gandara, J. von Pawel, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chemotherapy for cholangiocarcinoma: An update.

H. Cortés-Funes, N. Ramírez-Merino, S. P. Aix, 2013, World journal of gastrointestinal oncology.

RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

J. Shih, Keunchil Park, S. Novello, 2019, Journal of Clinical Oncology.

50P A phase Ib study of CC-90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (EP) or carboplatin (EC) in patients (Pts) with first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC): Updated results

L. Paz-Ares, I. Aronchik, M. Provencio, 2021 .

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

Toyoaki Hida, Keunchil Park, D. Gandara, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

LBA66 Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial

N. Girard, R. Stahel, S. Cedrés, 2021, Annals of Oncology.

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.

L. Sequist, Gregory Riely, E. Felip, 2020, The Lancet. Respiratory medicine.

1141PDCA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study

J. Lee, M. Ahn, Y. Bang, 2017 .

Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study.

J. Neal, E. Felip, R. Gentzler, 2020 .

Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): Final overall survival (OS) analysis

M. Ahn, T. Mok, J. Soria, 2016 .

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.

N. Reinmuth, I. Horváth, K. Syrigos, 2022, The Lancet. Respiratory medicine.